The present disclosure provides a method for producing erythroid cells and/or erythrocytes comprising culturing hematopoietic stem cells (HSCs) or erythroid cells with a population of immortalized mesenchymal stem cells (MSCs) or conditioned medium obtained from the immortalized MSCs, wherein the immortalized MSCs are genetically engineered with a survival gene. Also provided is a method of making a blood product for use in transfusions and a method for increasing hemoglobin synthesis.

The invention relates to an isolated cell having, after culturing a pluripotent stem cell (PSC) in a medium comprising a WNT agonist and an ACTIVIN antagonist, increased HOXA gene expression relative to a PSC not cultured in a medium comprising a WNT agonist and an ACTIVIN antagonist, wherein the cell with increased HOXA gene expression is capable of generating a definitive haematopoietic stem/precursor cell. The invention also relates to use of the cell for generating a definitive haematopoietic stem/precursor cell, and a method for differentiating a PSC into a definitive haematopoietic stem/precursor cell and a definitive haematopoietic stem/progenitor cell differentiated from a PSC by the method. The invention further relates to a therapeutic composition comprising a cell of the invention, and to therapeutic methods and uses of a cell of the invention. The invention also relates to a reporter cell comprising distinguishable SOX17 and RUNXIC reporters, for use in tracking the differentiation of a PSC into a definitive haematopoietic stem/progenitor cell.

Provided is a composition for accelerating cell proliferation, including an erythropoietin-derived peptide as an active ingredient. Due to having a simpler structure than that of the existing natural human erythropoietin, the composition easily passes through the tissue-blood barrier, exhibits excellent cell protective activity, does not cause side effects of cell proliferation, and improves a hematopoietic function. Accordingly, the composition is used in the treatment or prevention of an anemic disorder.

The present invention is in the field of pluripotent stem cells. In particular the invention relates to a method for (closed system) induction of differentiation of pluripotent stem cells towards a pre-selected cell type, such as, for example, cardiomyocytes or endothelial cells. The method as disclosed herein is particularly useful to upscale the production of cells derived from pluripotent stem cells, in particular (human) cardiomyocytes and/or endothelial cells derived from pluripotent stem cells.

Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.

Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered immune cells. Certain embodiments of the disclosure include compositions, cells, and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and may be suitable for allogeneic cellular therapy because they are HLA negative. In some aspects, the cells have imaging and suicide targeting capabilities.

Disclosed herein are methods of producing platelets and red blood cells using synthetic biology and uses thereof. The methods disclosed herein can also be used to produce platelets and red blood cells comprising a therapeutic agent. The cells produced by the methods disclosed herein can be used to treat, manage, prevent and diagnosis various diseases and disorders and be used as a research tool.

Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered T cells comprising at least one exogenous γδ T cell receptor, for example one that is selected to target a specific disease or pathogen (e.g., cancer or COVID-19). The T cells may be produced from human hematopoietic stem/progenitor cells and are suitable for allogeneic cellular therapy because they do not induce graft-versus-host disease (GvHD) and resist host immune allorejection. Consequently, such cells are suitable for off-the-shelf use in clinical therapy.

The present disclosure provides a method for producing red blood cells by using peripheral blood as well as the produced red blood cells.

Disclosed are compositions, systems and methods comprising a regenerative fibroblast cell, population or subsets thereof possessing regenerative activity useful for treatment of various degenerative diseases. In one embodiment, the disclosure provides fibroblasts with enhanced proliferative potential based on enrichment for CD105 and/or CD117 markers. In one embodiment, fibroblasts possessing CD105 and/or CD117 markers are further enriched for the property of rhodamine 123 efflux.